The CDC has ended its bird flu emergency response, now tracking H5N1 like it does with seasonal flu. This removes a key policy boost for Moderna, Novavax, CureVac, and Traws Pharma. Human case updates will be provided monthly, and animal data will be discontinued. Vaccine stocks experienced mixed sentiment, with retail investors remaining cautious as policy support waned.